Company news
Pharmala Biotech Holdings, Inc. (CSE:MDMA) news
Pharmala Biotech Holdings, Inc. news releases on 6ix. Latest, Sep 18, 2026: PharmAla Biotech Provides Corporate Update, Change of Auditor, Retention…
Press releases & updates
PharmAla Biotech Provides Corporate Update, Change of Auditor, Retention of Watertower Research and Oak Hill
September 18, 2026
PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill
September 17, 2026
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
August 21, 2026
PharmAla Issues Q3 Financial Statements and AGM Update
July 30, 2026
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
July 21, 2026
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
July 6, 2026
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
May 20, 2026
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
May 13, 2026
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
April 27, 2026
PharmAla Issues Q2 Financial Statements and Grants Options
April 21, 2026
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
April 20, 2026
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
March 3, 2026
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
February 26, 2026
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
February 23, 2026
PharmAla Announces Changes to Board of Directors
February 10, 2026
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
January 8, 2026
PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
December 24, 2025
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
December 15, 2025
PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules
December 10, 2025
PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital
November 3, 2025
PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists
October 8, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
October 2, 2025
PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand
September 25, 2025
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
September 19, 2025
PharmAla Completes Import of LaNeo MDMA for US Distribution
September 8, 2025
PharmAla Incorporates Australian Entity for Clinical Research
September 3, 2025
PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License
August 7, 2025
PharmAla Issues Q3 Financial Statements
July 25, 2025
PharmAla Files Preliminary Base Shelf Prospectus
June 20, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
June 3, 2025
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla
May 30, 2025
PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines
May 15, 2025
PharmAla Issues Q2 Financial Statements
April 30, 2025
PharmAla Contracts with Partner to Act as US Distributor
March 24, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
March 21, 2025
PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands
March 10, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study
March 3, 2025
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
February 27, 2025
The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News
January 27, 2023